We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)

News   Oct 09, 2009

 
ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
 
 
 

RELATED ARTICLES

E-cigarette Flavorings Change Chemistry & Create Irritants

News

The sweet flavors’ appeal to teens is a major concern for Food and Drug Administration officials, who recently declared teen vaping an epidemic. New research shows flavorings are transforming more than marketing. The chemical additives react to e-liquid, or e-juice, creating new compounds that could trigger irritation and inflammation when inhaled.

READ MORE

Proactive Approach Protects Population From HIV

News

A preventative approach to HIV drastically reduced the number of HIV diagnoses in New South Wales, Australia.

READ MORE

Treatment Eliminates Nicotine Addiction in Preclinical Tests

News

Scientists at Scripps Research have successfully tested a potential new smoking-cessation treatment in rodents.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE